Roche’s Genentech and Enable Injections, a developer and manufacturer of investigational wearable infusion devices for combination products, have partnered for multiple programs using Enable’s en-Fuse platform, a drug-delivery device designed for subcutaneous administration of large-volume drugs.  

Enable’s enFuse is an on-body drug delivery platform with a drug-transfer system compatible with standard syringes or vial container formats. The wearable enFuse platform is being developed for subcutaneous administration of large volumes potentially ranging up to 50 mL. The partnership includes the potential for multiple molecule development programs incorporating long-term manufacturing and supply arrangements.

Enable says enFuse has the potential to provide patients and their caregivers an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting.

Source: Enable Injections